10-K: DaVita Reports 2025 Results Amid Cyber Incident & Growth

DaVita Inc. reported a 6.5% increase in total consolidated revenues to $13.643 billion for fiscal year 2025, alongside a slight decrease in operating income and a significant share repurchase program.

Summary

• Total consolidated revenues increased 6.5% to $13.643 billion in 2025, up from $12.816 billion in 2024.
• U.S. dialysis revenue grew 3.5%, driven by an $18.24 increase in average patient services revenue per treatment.
• Other ancillary services revenue surged 27.3% to $1.922 billion, primarily from international operations.
• Operating income decreased 2.2% to $2.044 billion, while adjusted operating income increased 5.7% to $2.094 billion.
• Net income attributable to DaVita Inc. was $746.803 million, down from $936.342 million in 2024.
• Repurchased 12.679 million shares for $1.788 billion, resulting in a 14.9% net reduction in outstanding share count year-over-year.
• Experienced a cybersecurity incident in April 2025, incurring $25.2 million in charges and impacting billing/revenue collection.
• Net increase in consolidated patient growth of 4.9%, with international patient growth at 17.6% and 76 new international dialysis centers.
• Debt expense increased 23.4% to $580 million due to higher long-term debt balances and expiration of lower-rate interest rate caps.
• The effective income tax rate increased to 21.8% from 18.3% in 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed report. While revenue growth and strategic expansions are positive, the decline in net income, operating income, and cash flows, coupled with the impact of the cyber incident and rising costs, indicates significant headwinds. The ongoing legal and regulatory risks also contribute to a neutral-to-slightly-negative outlook.

Positives

• Strong revenue growth in ancillary services (27.3%) and overall consolidated revenue (6.5%) demonstrates business expansion and diversification.
• Significant share repurchase program, reducing outstanding shares by 14.9% year-over-year, indicates management's confidence and commitment to shareholder returns.
• Positive patient growth, especially in international markets (17.6%), highlights successful global expansion strategies.
• Successful refinancing of Term Loan A-1 and B-1 facilities, and issuance of new senior notes, optimizing the debt structure.
• Proactive hedging against interest rate increases with forward interest rate caps helps manage financial risk.
• Maintained leverage ratio within the target range of 3.0x to 3.5x, indicating sound financial management.
• U.S. Integrated Kidney Care (IKC) operating income increased by $40 million (222.2%) due to net shared savings and increased revenues from special needs plans.

Negatives

• Operating income decreased by 2.2% ($46 million) in 2025, indicating pressure on profitability despite revenue growth.
• Net income attributable to DaVita Inc. decreased by $189.539 million (20.2%) from 2024, impacting shareholder earnings.
• U.S. dialysis treatments decreased by 1.1%, primarily due to higher patient mortality and missed treatments from a more severe flu season.
• Operating cash flows decreased by 6.7% to $1.887 billion, and free cash flows decreased by 11.9% to $1.024 billion.
• Incurred $25.2 million in charges related to a cybersecurity incident, which also disrupted billing and revenue collection cycles.
• Increased equity investment losses at Mozarc Medical Holding LLC, including $46.4 million in impairment and restructuring charges.
• International operating income decreased by 29.9% ($38 million), partly due to a legal accrual in 2025 and a non-recurring gain on ownership change in 2024.
• Corporate administrative support expenses increased by 17.7% ($20 million), contributing to overall cost pressures.
• The effective income tax rate increased to 21.8% from 18.3% in 2024, reducing net earnings.

Risks

• Global health conditions, such as severe flu seasons and infectious diseases, may lead to elevated patient mortality, negatively impacting treatment volumes and new admissions.
• The complex and evolving governmental laws, regulations, and other requirements, including potential changes to Medicare/Medicaid reimbursement, could materially impact business operations and financial results.
• A decline in the number or percentage of patients with higher-paying commercial insurance due to economic conditions, legislative actions (e.g., 'One Big Beautiful Bill Act,' expiration of premium tax credits), or restrictive plan designs by payors could significantly reduce profitability.
• Inability to negotiate and maintain competitive contracts with private payors could lead to lower reimbursement rates or loss of patients.
• Increased labor costs due to nationwide shortages of skilled clinical personnel and inflationary pressures may outpace reimbursement rate increases, impacting margins.
• Supply chain disruptions, material price increases on supplies, or inadequate reimbursement for purchased drugs/equipment could negatively affect service provision and increase costs.
• Increased reliance on third-party service providers for critical functions poses risks of service disruption, loss of control, and challenges in securing timely or cost-effective alternatives.
• Cybersecurity attacks and privacy breaches, as experienced in April 2025, can lead to operational disruptions, data loss, financial penalties, and reputational harm.
• Significant risks are associated with estimating dialysis revenues and related refund liabilities, which are complex and subject to ongoing adjustments.
• Intense competition in the U.S. and international dialysis markets, including from new entrants and non-traditional providers, could adversely affect market share and growth.
• Acquisitions, mergers, joint ventures, and dispositions carry risks such as integration challenges, unknown liabilities, and antitrust scrutiny.
• Strategic and operational initiatives, particularly in Integrated Kidney Care (IKC) and home-based dialysis, are subject to risks of generating losses or being unsuccessful due to evolving regulatory environments and financial accountability for total patient costs.
• International operations expose the company to political, economic, legal, and operational risks, including labor cost increases, political instability, and foreign currency fluctuations.
• A substantial amount of indebtedness and restrictive debt covenants may limit intended uses of capital and reduce operational flexibility.
• Goals and disclosures related to ESG matters expose the company to reputational and financial risks if not met or accurately reported.
• Adverse changes in tax laws, regulations, and interpretations or challenges to tax positions could materially affect the effective tax rate and financial results.
• Liability claims for damages and other expenses that are not covered by insurance or exceed existing coverage could have a material adverse effect.
• Failure to successfully maintain an effective internal control over financial reporting could compromise financial reporting integrity and impact stock price.
• Provisions in organizational documents and Delaware law may deter changes of control or make it more difficult for stockholders to change the Board of Directors.

Future Outlook

The company expects approximately flat U.S. dialysis treatment volumes in 2026, anticipating slight improvement in flu impact compared to 2025 but continued elevated mortality. Operating income growth is projected from revenue per treatment improvements and collection efforts, partially offset by the expiration of enhanced premium tax credits for exchange plans. Costs per treatment are expected to increase due to inflationary pressures on labor and other costs, though mitigated by declining depreciation and amortization and reduced cyber incident costs. Positive operating income growth is also anticipated in international and integrated kidney care businesses, with a decrease in debt expense due to recent financing transactions. Considerable uncertainty remains regarding the impact of governmental laws and regulations on the business.

Management Comments

• Our patient-centric care model leverages our platform of kidney care services to maximize patient choice in both models and modalities of care.
• We believe that the flexibility we offer coupled with a focus on comprehensive kidney care supports our commitments to help improve equitable clinical outcomes and quality of life for our patients.
• Our caring culture fuels our continuous drive toward achieving our mission to be the provider, partner and employer of choice.
• We are always striving for improved productivity levels, however, changes in factors such as federal and state policies or regulatory billing requirements can lead to increased labor costs as can increases in turnover.
• We believe that our cash flows from operations and other sources of liquidity, including from amounts available under our senior secured credit facilities and our access to the capital markets, will be sufficient to fund our scheduled debt service under the terms of our debt agreements and other obligations for the foreseeable future, including the next 12 months.

Industry Context

StockSavvy.ai notes that DaVita's continued focus on integrated kidney care and home-based dialysis aligns with broader healthcare trends emphasizing value-based care, preventative measures, and patient convenience. The challenges faced, such as rising labor costs and intense competition, are common across the healthcare sector, particularly for large providers navigating complex regulatory environments and technological shifts. The increasing adoption of AI in healthcare, as mentioned by DaVita for personalized development, represents a significant industry-wide trend for efficiency and improved outcomes, but also introduces new compliance and security risks. The termination of certain CMMI payment models (ETC and KCF) reflects the dynamic and often unpredictable nature of government healthcare policy, requiring providers to be agile in their strategic investments.

Comparison to Industry Standards

• DaVita's 2025 U.S. dialysis market share of approximately 36% based on patient count positions it as a leading provider, comparable to its largest competitor, Fresenius Medical Care, which also operates globally and manufactures its own supplies, potentially offering cost advantages.
• The company's consistent industry leadership in the Centers for Medicare & Medicaid Services (CMS) Quality Incentive Program (QIP) for eleven years and CMS Five-Star Quality Rating System for ten years indicates strong clinical quality outcomes, often exceeding industry averages for ESKD patient care, a key differentiator in a competitive market.
• The underlying ESKD dialysis patient population grew at an approximate compound annual rate of 1.8% from 2013 to 2023 and 0.2% from 2018 to 2023, suggesting a relatively stable but slow-growing core market. This necessitates that providers like DaVita focus on market share gains and integrated care models for growth, similar to strategies seen in other mature healthcare segments.
• The approximately 15% utilization of home-based dialysis among ESKD patients in the U.S. in 2023, as reported by USRDS, highlights a significant growth area for DaVita, aligning with government initiatives (2019 Executive Order) to increase home dialysis adoption, a trend also actively pursued by competitors like Fresenius Medical Care.

Corporate Governance

Legal Proceedings

• **2020 U.S. Attorney New Jersey Investigation**: Subpoena and Civil Investigative Demand (CID) received in March 2020 regarding joint venture arrangements, medical director agreements, and compliance with a Corporate Integrity Agreement. The U.S. Attorney's Office for District of New Jersey decided not to intervene in U.S. ex rel. Doe v. DaVita Inc., which was dismissed without prejudice on April 13, 2022.
• **U.S. ex rel. Bayne v. DaVita Inc., et al. (Eastern District of Pennsylvania)**: The U.S. Attorney's Office decided not to intervene in October 2022. An amended complaint was unsealed, alleging federal and state False Claims Act violations. A fourth amended complaint was filed on November 8, 2023. The company's motion to dismiss was denied on April 29, 2025, and the company answered the complaint on July 21, 2025. The company disputes allegations and intends to defend.
• **2020 California Department of Insurance Investigation**: Investigative Subpoenas received in April 2020, September 2020, and September 2021, requesting information on patient communications about insurance plans, financial assistance from the American Kidney Fund (AKF), and donations to AKF. The company is cooperating.
• **2023 District of Columbia Office of Attorney General Investigation**: A CID was issued in January 2023 in connection with an antitrust investigation into the AKF, covering communications with AKF, donations, and communications with patients, providers, and insurers regarding AKF. The company is cooperating.
• **2024 Federal Trade Commission Investigation**: Two CIDs were received in April 2024 for an industry investigation under Section 5 of the Federal Trade Commission Act regarding the acquisition of medical director services and provision of dialysis services, seeking information on restrictive covenants (non-competes) with physicians. The company is cooperating.
• **2021 Antitrust Indictment and Putative Class Action Suit**: An indictment was returned on July 14, 2021, against the company and its former chief executive officer for alleged agreements not to solicit senior-level employees (Sherman Act Section 1 violation). A jury acquitted both on April 15, 2022. A consolidated putative class action complaint was filed on August 9, 2021, in In re Outpatient Medical Center Employee Antitrust Litigation, alleging Sherman Act Section 1 violations. A Third Amended Complaint was filed on October 27, 2024, and the company responded on December 20, 2024. Plaintiffs filed a motion to certify the class on September 15, 2025. The company disputes allegations and intends to defend.

Related Party Transactions

• The company has a share repurchase agreement with Berkshire Hathaway Inc., under which it repurchases shares to maintain Berkshire's aggregate beneficial ownership at 45.0% of outstanding common stock.
• As of December 31, 2025, the company had a repurchase obligation to Berkshire for $199.940 million, recorded as 'due to related party' on the consolidated balance sheet. This obligation was settled on January 29, 2026, for 1,658 shares.
• Berkshire Hathaway Inc. is subject to a standstill agreement restricting the acquisition of additional shares and requiring voting in accordance with the Board's recommendations for shares exceeding 40% ownership.

Stakeholder Impact

• **Shareholders**: Impacted by the significant share repurchase program, which reduces share count and could support earnings per share, but also by the decline in net income and operating cash flows. Ongoing legal proceedings and regulatory changes introduce potential volatility to share price.
• **Patients**: Directly impacted by the quality of care, access to home-based dialysis, and integrated kidney care initiatives. Potential for reduced access to commercial insurance due to policy changes or restrictive plan designs could affect their treatment options and costs.
• **Employees (Teammates)**: Affected by rising labor costs and competition for skilled personnel, which the company addresses through human capital management, career development programs, and a comprehensive total rewards package. Union organizing activities could impact employee relations and operational flexibility.
• **Physician Partners**: Relationships are crucial for patient referrals and medical director services. These relationships are subject to scrutiny under anti-kickback and Stark Law regulations, and competition for affiliations.
• **Payors (Commercial & Government)**: Engaged in continuous negotiations over reimbursement rates and plan designs. Government payors (Medicare, Medicaid) determine a significant portion of revenue, and changes in their policies directly impact the company's financial health.
• **Suppliers**: Affected by supply chain disruptions and pricing negotiations for pharmaceuticals and medical supplies, which can impact the company's ability to provide services and manage costs.
• **Creditors**: Affected by the company's substantial indebtedness and its ability to generate sufficient cash flows to service debt obligations, although the company believes its liquidity sources are adequate for the foreseeable future.

Next Steps

• Continue to implement cost control initiatives, including labor productivity, in 2026 to manage operating costs.
• Invest in developing capabilities and executing strategic priorities, including information technology and integrated kidney care.
• Assess the effect of new accounting standards (ASU 2024-03 and ASU 2025-06) on consolidated financial statements.
• Leverage artificial intelligence to increase access to personalized development for teammates, supporting career objectives.
• Complete the acquisition of a noncontrolling minority interest in Elara Caring in 2026, subject to regulatory approvals.
• Monitor Medicare Advantage (MA) notices, regulatory updates, and guidance, as well as enforcement for impact on business.
• Evaluate medium cut-off dialyzers for use in the U.S. for enhanced middle molecule clearance.

Key Dates

Recommendation

DaVita's 2025 performance shows resilience in revenue growth and strategic expansion, particularly internationally and in integrated care. However, the decline in net income and operating cash flows, coupled with significant cybersecurity costs and ongoing legal/regulatory uncertainties, presents a mixed financial picture. The aggressive share repurchase program is a positive for shareholders, but the substantial debt and rising labor costs are headwinds. A seasoned investor would likely maintain a 'hold' position, awaiting clearer trends in profitability and resolution of key risks before making a more decisive move.

Keywords

Kidney Care, Dialysis, ESKD, CKD, Healthcare Provider, Integrated Kidney Care, Home Dialysis, SEC Filing, 10-K, Financial Results, Cybersecurity, Patient Growth, Share Repurchase, Debt Refinancing, Medicare, Medicaid, Commercial Insurance, Risk Management, Corporate Governance, International Operations